Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
TE-1146, a novel anti-CD38-lenalidomide conjugate, demonstrates potent ex vivo activity in an assay that could select sensitive pts, while resistance correlated with lower CD38 and/or higher expression of CD56 and/or CD138.”
Title: TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity
Authors: Shih-Syuan Cheng, Jing-Gu Jiang, Shih-Chiang Lin, Yueh-Hsiang Yu, Tse Wen Chang, Carmay Lim, Yuan-Bin Yu, Hsing-Mao Chu
You can read the Full Article in Haematologica.
You can find more posts featuring Robert Orlowski on OncoDaily.
